cavosonstat

At a time when Nivalis Therapeutics Inc (NASDAQ: NVLS) is being thrashed with multiple downgrades, H.C. Wainwright maintains its Buy rating, despite the announcement of a trial miss. Trial Miss And Share Reaction Shares of Nivalis plunged to a new 52-week low of $2.58 after it reported that the...